As an expert in the field of structural biology, Creative Biostructure offers MagHelix™ FBDD Platform, an integrated platform covering the entire FBDD process, equipped with advanced biophysical detection instruments, providing customized drug discovery solutions for a wide range of disease areas and therapeutic targets.
Fragment-based drug discovery (FBDD) is a powerful approach to develop effective small molecule compounds that start with fragments that weakly bind the target. Because FBDD has many advantages over high-throughput screening activities, it becomes an attractive strategy in target-based drug discovery. Many effective compounds/inhibitors of various targets have been developed using this approach. Fragment screening and understanding of the methods used in fragment binding modes are critical in FBDD.
Creative Biostructure has established the MagHelix ™ FBDD platform for early drug discovery, covering advanced biophysical detection instruments, such as X-ray single crystal diffractometer, high-performance nuclear magnetic resonance (NMR) instruments, and surface plasmon resonance (SPR) instruments. With the help of the FBDD platform, Creative Biostructure can provide customized drug discovery solutions for various disease areas and therapeutic targets, including complex targets involving protein-protein interactions (PPIs).
• Enhanced probability in finding active small molecules
• Drug design with higher activity and selectivity
• Reduced drug development costs
• Customized drug discovery solutions for various therapeutic targets and disease areas
• Identifying weakly bound fragments to facilitate PPI targeting (flat binding pockets)
• Evolving active fragments into potential lead compounds according to the 3D structures of target proteins
“The design of our FBDD fragment library follow the ‘Rule-of-Three’ (RO3) and the fragment library size is considered according to the selected screening method.” Said Joanna, the chief marketing staff at Creative Biostructure.
According to Joanna, the company also provides various orthogonal biophysical approaches to confirm the exact binding fragments, such as X-ray crystallography, saturation transfer difference (STD) NMR, cryo-electron microscopy (Cryo-EM), thermal shift assay (TSA), surface plasmon resonance (SPR), bio-layer Interferometry (BLI), etc.
To know more information about the MagHelix™ FBDD Platform provided by Creative Biostructure, please visit https://drug-discovery.creative-biostructure.com/maghelix-fbdd-platform-p60.